Caricamento...

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET

HQP8361 (MK8033) is a novel and selective MET kinase inhibitor that has completed a phase I clinical trial. AZD9291 (osimertinib) represents the first-approved third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR muta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Yu, Danlei, Li, Yiting, Sun, Keven DY, Gu, Jiajia, Chen, Zhen, Owonikoko, Taofeek K, Ramalingam, Suresh S, Sun, Shi-Yong
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642664/
https://ncbi.nlm.nih.gov/pubmed/33163272
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !